N99-02: Melphalan and Buthionine Sulfoximine (BSO)

New Approaches to Neuroblastoma Therapy (NANT) Consortium

Status and phase

Completed

Phase 1

Conditions

Neuroblastoma

Treatments

Procedure: Peripheral blood stem cell infusion

Drug: buthionine sulfoximine

Drug: melphalan

Other: Filgrastim

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT00005835

P01CA081403 (U.S. NIH Grant/Contract)

CDR0000067849

NANT-99-02

Details and patient eligibility

About

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of melphalan and buthionine sulfoximine followed by bone marrow or peripheral stem cell transplantation in treating children who have resistant or recurrent neuroblastoma.

Full description

OBJECTIVES:

Determine the maximum tolerated dose of melphalan when combined with buthionine sulfoximine and followed by autologous bone marrow or peripheral blood stem cell support in children with resistant or recurrent high-risk neuroblastoma.
Assess the toxic effects of this regimen in these patients.
Determine the pharmacokinetics of this regimen in these patients.
Determine the response rate of patients treated with this regimen.

OUTLINE: This is a multicenter, dose-escalation study of melphalan.

Patients receive buthionine sulfoximine IV as a bolus over 30 minutes followed by a 72-hour continuous infusion beginning on day -4; melphalan IV over 15 minutes on days -3 and -2; autologous peripheral blood stem cells or bone marrow IV over 15-30 minutes on day 0; and filgrastim (G-CSF) subcutaneously or IV once daily beginning on day 0 and continuing until blood counts recover.

Cohorts of 3-6 patients receive escalating doses of melphalan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients are followed at 84 days and then 2 months later if there is a complete and/or partial response. Patients who continue therapy on other protocols are followed before starting the new therapy. All patients are followed for life for any delayed toxic effects to protocol therapy and secondary malignancies.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 2-3 years.

Enrollment

31 patients

Sex

All

Ages

Under 30 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients have relapsed neuroblastoma and must have exhausted all other options for treatment before they can be considered for treatment on this study.
Relapsed patients who are greater than 6 months since having a stem cell transplant can enter on this study.
Patients must have stem cells collected and stored before starting treatment.
Patients must have a double lumen central venous line in place.
Patients must have adequate kidney and liver function measured by blood tests and test of renal function (creatinine clearance or glomerular filtration rate (GFR)).
Patients must have normal heart and lung function measured by lack of physical evidence or clinical history of difficulties breathing and tests of cardiac function (Echocardiogram or MUGA evaluation).
Patients must have an essentially normal neurological exam.
Patients must have one entire kidney that has not had any radiation at treatment doses. (Xrays and scans are ok).
Patients must have recovered from the effects of any prior treatment for their tumor.

Exclusion criteria

They have had any radiation therapy to the brain.
They have known history of or current tumor found in the brain or surrounding tissues.
They have a history of seizures.
They have a history of changes in a test of kidney function with antibiotic use in the 6 months immediately before entering on this study.